Semax explained · identity, human studies and limits
Semax has been studied in people. What those studies measured matters more than the word “nootropic.”
Semax is a synthetic seven-amino-acid peptide studied for effects on neuronal signaling, responses to brain injury and cognitive processes. Small human studies and a much larger body of cell and animal research exist. They do not establish reliable memory enhancement, an ADHD treatment, or a safe self-use regimen.
Start with its exact identity, then follow the evidence from a molecular signal to a brain scan to an outcome a person can notice.
What is Semax, exactly?
Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP. The first four residues correspond to positions 4–7 of adrenocorticotropic hormone, or ACTH. The Pro-Gly-Pro tail replaces the last three residues of the native ACTH(4–10) fragment. This is why papers use both “ACTH(4–7)-PGP” and “ACTH(4–10) analogue.” It is not the full ACTH hormone.
Seven residues, two origins
Sequence shared with ACTH(4–7)Pro · Gly · Pro
Added tripeptide tail
The defined neutral Semax reference has formula C37H51N9O10S and a molecular weight of approximately 813.93 g/mol. FDA lists the corresponding acetate reference separately at approximately 874.0 g/mol. A salt designation, counterion content and the amount of peptide in a sample therefore deserve separate attention. A product name alone does not resolve all of them. FDA chemistry review, Table 1; PubChem reference.
Acetate is different from N-acetyl Semax
An acetate salt does not mean the peptide has been covalently acetylated. In a 2016 chemistry study, acetylating Semax’s N-terminus changed its copper coordination. The acetylated material did not provide the same protection from copper-induced toxicity in SH-SY5Y cells as the peptide with a free N-terminus. That is a concrete reason to avoid transferring results between differently modified materials, including products described as acetylated or amidated variants.
What do the human studies actually show?
Human research exists, but it answers several different questions. Healthy-volunteer imaging can test whether brain activity changes. A rehabilitation study can examine daily function after illness. Neither automatically demonstrates better focus in a healthy person.
A measurable brain-network effect
A 2018 resting-state fMRI study included 14 participants receiving Semax and 10 receiving placebo. Scans before exposure and at 5 and 20 minutes showed a difference in the rostral, or frontward, part of the default mode network. This is a network-level measurement. It is not a demonstrated improvement in memory, work output or a clinical symptom.
Connectivity, with an important denominator
A 2020 study examined Semax, Selank and placebo across 52 healthy participants. It reported changes involving right-amygdala connectivity with temporal regions. The number 52 is the whole study, not 52 Semax exposures. FDA also notes possible overlap between Semax participants in the 2018 and 2020 reports. These should not be added together as two proven independent cohorts.
A symptom signal without slowed disease progression
The 2007 report describes an open-label study in sequential groups. Semax did not alter denervation progression or the course of the clinical functional estimates. The authors reported improved emotional state and motivation within quality-of-life assessment. An open-label quality-of-life result is not evidence that the disease was slowed. The abstract’s explicit design description also matters more than a database’s trial-type tag.
A newer human paper does not necessarily isolate Semax. A 2026 retinal-surgery study followed 42 patients. Both groups received Semax, while one received a different delivery approach plus additional physiotherapy. Its reported advantage concerns the combined approach. It cannot establish what Semax alone contributed.
The focused ClinicalTrials.gov searches for Semax/Semaks and the Semax intervention name returned no records when checked for this guide. That result describes those registry searches; the published studies above still exist.
Stroke research is more specific than a “brain recovery” claim
An older acute-stroke report compared 30 patients receiving Semax within combined care with 80 controls receiving conventional therapy. It reported faster improvement on neurological measures. Its abstract does not establish a blinded, randomized comparison, and it cannot support an everyday cognitive-enhancement claim.
The 2018 rehabilitation paper followed a different group of 110 patients over five months. The full report separates early and late rehabilitation and then compares subgroups with and without Semax. All groups received rehabilitation and other treatment.
One study, four subgroups
60 participants30with Semax30without Semax
50 participants30with Semax20without Semax
Blood measurement
Plasma BDNF increased more in Semax subgroups. Blood BDNF is not a direct measurement of the amount or action of BDNF inside the brain.
Daily function
Barthel Index gains occurred sooner with Semax. By five months, earlier-rehabilitation group means were 85.8 with and 84.1 without Semax.
Muscle strength
The full report gives a weaker case for a distinct Semax effect on paresis. Earlier rehabilitation was an important determinant of recovery.
The useful finding is a possible benefit within a specific rehabilitation setting. The limits matter: the report mentions randomization at enrollment but does not describe allocation adequately, has no placebo group, and combines treatment with rehabilitation. Its positive BDNF and Barthel findings do not make every endpoint positive or establish a benefit in healthy adults.
Why does FDA’s summary sound narrower? Its July 2026 briefing explicitly says Russian-language full stroke papers, including Gusev 2018, were not included in its effectiveness evaluation because English full translations were unavailable to that review. This guide examined the Russian full report. That explains a difference in the evidence considered; it does not turn the study into decisive proof or override FDA’s assessment. FDA briefing, pages 23–25.
BDNF is a research clue, not a single “brain boost” switch
BDNF is a protein involved in neuronal function and plasticity. A 2006 rat study reported a maximum 1.4-fold increase in hippocampal BDNF protein and changes in TrkB signaling after Semax. These were animal measurements. They do not quantify a human memory benefit or show that Semax directly binds and activates TrkB.
Direction also depends on where and when a measurement is made. A 2009 rat experiment found early decreases as well as increases in neurotrophin gene expression.
Several mechanisms are being investigated
| Experiment | What was observed | What remains unproven |
|---|---|---|
| Rat ischemia–reperfusion | RNA sequencing found 394 differentially expressed genes after Semax versus saline, with inflammatory and neurotransmission-related expression patterns moving in different directions. 2020 study | A gene-expression pattern is not a demonstrated clinical recovery rate. |
| Female mice with spinal cord injury | Improved motor-test outcomes and changes involving USP18, FTO deubiquitination and lysosomal injury were reported. Network pharmacology and docking implicated μ-opioid receptors. 2025 study | The available abstract does not establish human receptor occupancy, a clinical analgesic effect or a human safety profile. |
| Copper–amyloid chemistry and cultured cells | Semax extracted copper from a copper–amyloid complex and reduced associated oxidative reactions; SH-SY5Y cells showed protection in that experimental system. 2025 study | This is not evidence that Semax removes amyloid or treats Alzheimer’s disease in people. |
| Male APP/PS1 transgenic mice | Semax and a separately tested derivative affected behavioral tests and reduced amyloid inclusions. Individual behavioral endpoints were not uniformly improved. 2025 study | A disease model and a modified peptide cannot establish human efficacy for the unmodified research material. |
On smaller screens, scroll the table sideways to read the final column. Each row represents a different experimental setting; the mechanisms are not one proven causal pathway in humans.
Does Semax help ADHD, focus or mood?
The often-cited 2006 ADHD and Rett syndrome paper is a hypothesis, not an ADHD treatment trial. It proposes that dopamine- and BDNF-related findings might be worth investigating. The focused search for this guide did not identify a controlled Semax trial establishing ADHD efficacy. FDA likewise states that it did not evaluate ADHD in the 2026 review because supporting literature for that use was not found.
“Not a stimulant” does not mean interaction-free
A rodent neurochemistry study found that Semax alone did not change the measured tissue or extracellular dopamine concentrations. However, it enhanced amphetamine-induced dopamine release and locomotor activity. The same study reported serotonin-metabolite changes. These are context-dependent observations, not evidence that Semax reliably increases dopamine by itself or that a combination is safe.
A 2024 chronic-stress experiment in male rats found improvements in sucrose preference and hippocampal BDNF measures with Semax. The forced-swim test did not show an effect on immobility. That mixed result should remain visible when interpreting an “antidepressant-like” title. It is not a depression treatment trial in people.
For a reader asking whether Semax will make them more focused, energized or emotionally resilient, the accurate answer is that the studies reviewed here do not establish a predictable benefit. Self-reported online experiences cannot resolve placebo effects, other substances, different preparations or differences between individuals.
Minutes on a scan are not a duration-of-benefit result
Animal tracer work and peptide-degradation experiments show that Semax can be broken into smaller fragments. The identity of the measured signal matters: intact peptide, a metabolite and total radioactivity are different measurements. A downstream molecular change can also have a different time course from the parent peptide.
FDA’s 2026 review did not identify human pharmacokinetic studies for Semax free base or acetate by any route. Rat distribution measurements and a scan taken shortly after exposure cannot supply a validated human dosing interval, a reliable “all-day” effect or an administration recommendation.
Side effects and approval status: what is known?
Semax is not an FDA-approved drug. FDA’s July 2026 advisory materials evaluate free base and acetate for the separate question of compounding from bulk substances. The briefing documents are agency staff evaluations, and advisory recommendations are not finished-drug approvals. Foreign use or a retail listing does not establish US approval or the suitability of a research vial for human administration. Official meeting materials.
Some human reports describe favorable tolerability. For example, the 2018 rehabilitation report states that no side effects were observed and that most patients rated tolerability well. This does not estimate rare risks, long-term safety or the effects of a different formulation. Many reports assessed by FDA did not discuss adverse events adequately.
Four safety gaps remain important: limited human pharmacokinetics; limited systematic adverse-event reporting; uncertainty about immune reactions and peptide-related impurities or aggregates; and differences between tested nasal preparations, other delivery systems and research materials.
The FDA briefing describes a consumer report of eye pain and burning, with hospitalization reported after use of an online nasal product. A spontaneous report cannot establish causation or frequency. It is still inconsistent with a blanket claim that there are no reported adverse events. FDA also discusses possible bleeding and drug-interaction concerns from the pharmacology, while emphasizing the limited clinical evidence.
There is no sound basis here to promise that Semax is nonaddictive, free of withdrawal effects, safe in pregnancy, or suitable for long-term unsupervised use. A lack of adequate studies is an uncertainty, not proof of either harm or safety. FDA safety assessment, pages 34–41.
How to match a research material to a paper
Check the sequence and terminal modifications first, then the salt or counterion designation, formulation and analytical record. A paper using a defined nasal preparation does not validate a lyophilized reagent, and a chromatographic purity result does not prove sterility, biological activity or clinical safety.
For an Apex research configuration, the Semax product listing is the commercial handoff. Consult the applicable record in the Lab Verified library, matching the named material and sample or lot identifier. The COA reading guide explains why identity, chromatographic purity and peptide content answer different questions.
Keep the comparison separate
Semax and Selank share a tripeptide tail but differ in their remaining sequence and research history. The Selank–Semax research comparison examines those differences. A shared structural feature is not a reason to combine them or transfer evidence between them.
Frequently Asked Questions About Semax
What is Semax?
Semax is a synthetic seven-amino-acid peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, or MEHFPGP. It combines the ACTH(4–7) sequence with a Pro-Gly-Pro tail. It is studied for effects on neuronal signaling and responses to injury; its relationship to ACTH does not make it equivalent to the full hormone.
What does Semax do to the brain?
In experimental systems, Semax can change neurotrophin expression, inflammatory signaling and neurotransmitter-related measurements. Small human fMRI studies detected changes in resting brain networks. Those measurements do not by themselves establish better memory, attention or everyday performance.
Are there human studies of Semax?
Yes. Published reports include small healthy-volunteer imaging studies, stroke rehabilitation cohorts and an open-label motor-neuron-disease study. Their designs, populations and endpoints differ. The evidence should not be summarized either as no human studies or as conclusive proof of broad cognitive enhancement.
Does Semax work for ADHD?
The frequently cited 2006 ADHD paper proposes a hypothesis using earlier biological and animal findings; it is not an ADHD treatment trial. The focused literature search for this guide did not identify a controlled trial establishing Semax efficacy for ADHD.
Is Semax a stimulant?
Semax is a peptide, and the available studies do not establish that it acts like a conventional stimulant in people. In one rodent experiment it did not increase dopamine measurements on its own, but it enhanced an amphetamine response. That is an interaction signal, not evidence that combining the substances is safe or useful.
How long does Semax take to work, and how long does it last?
Human fMRI measurements made 5 and 20 minutes after exposure describe scan timing, not the onset or duration of a meaningful benefit. Rat tracer and degradation studies cannot supply a reliable human half-life or a schedule for sustained cognitive effects.
What are the side effects and safety risks of Semax?
The human safety evidence is too limited to give reliable frequencies for common or rare adverse effects. Some reports describe good tolerability, but many do not report adverse events adequately. FDA has identified gaps involving human pharmacokinetics, immunogenicity, impurities, formulation quality and route-specific safety.
Is Semax FDA approved?
Semax is not an FDA-approved drug. FDA evaluated Semax free base and Semax acetate for a July 2026 compounding advisory meeting. Consideration of a bulk substance for compounding is a separate process from approval of a finished drug and does not establish that a retail research material is safe or effective for human use.
Are Semax acetate and N-acetyl Semax the same?
No. An acetate salt and covalent acetylation of the peptide are different chemical changes. A primary chemistry study found that N-terminal acetylation changed copper coordination and lost a protective effect observed with the unmodified peptide in a cell experiment. Results should be matched to the exact material tested.
How is Semax different from Selank?
They are different seven-residue peptides with different sequences and research histories. Sharing a Pro-Gly-Pro tail does not make their effects interchangeable. The dedicated Selank–Semax comparison explains the differences without treating either one as an established substitute for clinical care.
Primary references and source notes
The cited studies below were checked against current NCBI records. Full reports were examined where available, including the 2018 stroke rehabilitation paper and the 2025 copper and transgenic-mouse experiments. Other study descriptions are limited to the available abstracts. Registry searches and FDA records were checked separately; a search result count is not a count of clinical trials.
- Magrì A et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of inorganic biochemistry. 2016. PMID: 27586814.
- Dolotov OV et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research. 2006. PMID: 16996037.
- Shadrina M et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of molecular neuroscience : MN. 2010. PMID: 19662538.
- Eremin KO et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical research. 2005. PMID: 16362768.
- Tsai SJ et al. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Medical hypotheses. 2007. PMID: 16996699.
- Lebedeva IS et al. Effects of Semax on the Default Mode Network of the Brain. Bulletin of experimental biology and medicine. 2018. PMID: 30225715.
- Panikratova YR et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020. PMID: 32342318.
- Gusev EI et al. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 1997. PMID: 11517472.
- Gusev EI et al. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018. PMID: 29798983.
- Serdiuk AV et al. [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2007. PMID: 18379501.
- Sheludchenko VM et al. [Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome]. Vestnik oftalmologii. 2026. PMID: 42366656.
- Filippenkov IB et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes. 2020. PMID: 32580520.
- Liu R et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British journal of pharmacology. 2025. PMID: 40692165.
- Tomasello MF et al. Semax, a Copper Chelator Peptide, Decreases the Cu(II)-Catalyzed ROS Production and Cytotoxicity of aβ by Metal Ion Stripping and Redox Silencing. Bioinorganic chemistry and applications. 2025. PMID: 40496623.
- Radchenko AI et al. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta naturae. 2025. PMID: 41479572.
- Zolotarev IuA et al. [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Bioorganicheskaia khimiia. 2006. PMID: 16637290.
- Inozemtseva LS et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European journal of pharmacology. 2024. PMID: 39442746.
This guide explains research evidence and its limits. It does not recommend an administration route, dose, combination or treatment. Apex research materials are not supplied for human or veterinary use.
